Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: J Am Coll Surg. 2018 Jan 5;226(4):615–621. doi: 10.1016/j.jamcollsurg.2017.12.026

Table 3. Crude and Adjusted Hazard Ratios and 95% Confidence Intervals for Live Donor ABO-Incompatible Transplantation 2000 to 2015, Patient Survival, All-Cause Graft Failure, and Death Censored Graft Failure.

Follow-up Patient survival All-cause graft failure Death censored graft-failure
Crude HR (95% CI) aHR (95% CI)* Crude HR (95% CI) aHR (95% CI) Crude HR (95% CI) aHR (95% CI)
1-y 1.81 (1.26-2.60) 1.74 (1.15-2.63)* 2.23 (1.78-2.79) 2.27 (1.76-2.93) 2.42 (1.85-3.17) 2.34 (1.85-2.96)
3-y 1.55 (1.21-1.98) 1.51 (1.15-1.99) 1.71 (1.44-2.03) 1.70 (1.41-2.06)§ 1.83 (1.47-2.26) 1.82 (1.45-2.27)
*

Adjusted for recipient race and age at transplant, HLA mismatches GT 3, maximum PRA, previous kidney transplant, dialysis years, presence of diabetes at transplant, donor age, transplant center and transplant year.

Adjusted for recipient race and age at transplant, maximum PRA, previous kidney transplant, dialysis years, presence of diabetes at transplant, donor age, transplant center and transplant year.

Adjusted for recipient race, HLA mismatches GT 3, maximum PRA, dialysis years, presence of diabetes at transplant, donor age, transplant center and transplant year;

§

Adjusted for recipient race, HLA mismatches GT 3, maximum PRA, previous kidney transplant, dialysis years, presence of diabetes at transplant, donor age, transplant center and transplant year;

Adjusted for recipient race, HLA mismatches GT 3, maximum PRA, dialysis years, donor age, transplant center and transplant year.

aHR, adjusted Hazard Ratio; HLA mismatches GT3, human leukocyte antigen greater than 3; PRA, panel reactive antibody.